Advertisement
Advertisement
EDIT
Editas Medicine, Inc. Common Stock
2.50
USDSponsored
-0.25
-8.91%
Nov 10, 15:59 UTC -5
Closed
After-Market
2.54
+0.03
+1.20%
Editas Medicine, Inc. Common Stock (EDIT) Earnings
EDIT Earnings Reports
Positive Surprise Ratio
EDIT beat 26 of 44 last estimates.
59%
Next Report
Date of Next Report
Mar 08, 2027
Estimate for Q4 26 (Revenue/ EPS)
$6.90M
/-$0.18
Implied change from Q3 26 (Revenue/ EPS)
-33.48%
/+20.00%
Implied change from Q4 25 (Revenue/ EPS)
-72.12%
/+200.00%
Editas Medicine, Inc. Common Stock earnings per share and revenue
On Nov 09, 2026, EDIT reported earnings of -0.15 USD per share (EPS) for Q3 26, beating the estimate of -0.19 USD, resulting in a 22.04% surprise. Revenue reached 10.37 million, compared to an expected 4.55 million, with a 127.96% difference. The market reacted with a +7.00% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.18 USD, with revenue projected to reach 6.90 million USD, implying an increase of 20.00% EPS, and decrease of -33.48% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Editas Medicine, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Editas Medicine, Inc. Common Stock reported EPS of -$0.15, beating estimates by 22.04%, and revenue of $10.37M, 127.96% above expectations.
How did the market react to Editas Medicine, Inc. Common Stock's Q3 2026 earnings?
The stock price moved up 7%, changed from $2.57 before the earnings release to $2.75 the day after.
When is Editas Medicine, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 08, 2027.
What are the forecasts for Editas Medicine, Inc. Common Stock's next earnings report?
Based on --
analysts, Editas Medicine, Inc. Common Stock is expected to report EPS of -$0.18 and revenue of $6.90M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.